Advertisement
JNJ or PRAX or VRTX
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Praxis Precision Medicines (PRAX) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- JNJ exhibits stability with a market cap over $579 billion, recent FDA approvals like TECVAYLI for multiple myeloma, and year-to-date gains of about 16%, bolstered by a strong dividend history.
- PRAX, a clinical-stage biotech, shows explosive growth with 1-year returns exceeding 700% and shares near $310, driven by NDA submissions for ulixacaltamide and relutrigine in CNS disorders.
- VRTX maintains steady performance around $456 with a $116 billion market cap, supported by positive JOURNAVX pain management data and expansions in CF therapies.
- Relative performance highlights PRAX's high momentum but elevated risk, contrasting JNJ's defensive positioning and VRTX's balanced growth in recent market activity.
- Valuation sensitivity varies: JNJ trades at reasonable multiples with pipeline upside, while PRAX reflects biotech volatility and VRTX shows premium pricing on established revenue.
- Sector exposure in healthcare underscores trade-offs between large-cap reliability and small-cap catalysts in the current environment.
Introduction
This stock comparison evaluates JNJ, a diversified healthcare giant; PRAX, a precision neuroscience biotech; and VRTX, a leader in cystic fibrosis and emerging therapies. Traders seeking stability may favor JNJ's scale, while growth-oriented investors eye PRAX's momentum and VRTX's pipeline. Recent market activity, including FDA milestones and clinical readouts, highlights relative performance differences, aiding decisions on positioning amid healthcare sector volatility and broader economic shifts.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) operates across pharmaceuticals, medtech, and consumer health, with a market cap exceeding $579 billion. In recent weeks, shares traded around $240, reflecting year-to-date gains of approximately 16% and 1-year returns near 44%. Sentiment has been buoyed by FDA approval of TECVAYLI combined with DARZALEX FASPRO for relapsed/refractory multiple myeloma, positioning it as a potential early-line standard, alongside a Bank of America price target hike to $253 on pipeline strength. Investments over $1 billion in U.S. cell therapy manufacturing and Fast Track designation for nipocalimab in SLE further enhance long-term growth prospects. Price behavior shows resilience, with 52-week highs near $252, driven by oncology and immunology catalysts amid stable demand for established products.
PRAX Overview and Recent Performance
Praxis Precision Medicines (PRAX) focuses on CNS disorders via small molecules and ASOs, with a clinical-stage pipeline targeting epilepsy and tremors. Shares hover near $311, with 1-year returns surpassing 720% and 3-year gains over 1,700%, reflecting biotech momentum. Recent market activity features NDA submissions for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A DEEs, plus Phase 3 advancements for vormatrigine and elsunersen, with topline data expected in early 2026. Cash reserves near $1.5 billion post-offering support operations into 2028. Volatility persists, with 52-week range from $27 to $356, fueled by pipeline catalysts but tempered by net losses and no revenue, influencing high-beta sentiment.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) specializes in CF therapies and expands into pain, neurology, and renal cell disease, boasting a $116 billion market cap. Shares around $457 show modest YTD gains of 0.7%, with recent dips amid 52-week highs of $520. Positive Phase 4 data on JOURNAVX for post-surgical pain, enabling 91% opioid-free recovery, bolsters non-opioid positioning, alongside TRIKAFTA label expansions. Q4 2025 revenue hit $3.19 billion, up 10%, with 2026 guidance at $12.95-13.1 billion. Performance reflects pipeline consistency in CF dominance and diversification, with lower beta (0.31) supporting relative stability in volatile biotech conditions.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that analyze thousands of tickers across diverse strategies, timeframes, and market conditions. Only those demonstrating superior adaptability—like annualized returns up to 227% in semiconductors, 125% in aerospace/defense, or 80% in industrials with win rates of 70-95% and profit factors exceeding 3.0—earn a spot in this dynamic section. These bots employ pattern recognition, momentum, and volatility signals for short-term trades, outperforming benchmarks in recent volatility. Explore Trending AI Robots to identify strategies suited to healthcare momentum or defensive plays.
Head-to-Head Comparison
JNJ’s diversified model contrasts PRAX’s precision CNS focus and VRTX’s CF-centric expansion. Growth drivers differ: JNJ leverages oncology approvals and manufacturing scale; PRAX bets on NDA catalysts; VRTX advances pain and renal pipelines. Recent momentum favors PRAX’s multi-fold gains versus JNJ and VRTX’s steadier climbs. Risk profiles highlight JNJ’s low volatility and dividends against PRAX’s clinical-stage uncertainties (beta 3.01). All share healthcare exposure, but JNJ shows valuation resilience, PRAX premium pricing on upside, and VRTX sensitivity to CF dynamics. Sentiment tilts toward catalysts, balancing stability trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ for its trend consistency, pipeline catalysts like TECVAYLI and nipocalimab, and relative stability amid biotech volatility. Observable factors—defensive market positioning, manufacturing investments, and outperformance versus peers—suggest higher probability of sustained gains over PRAX’s momentum risks or VRTX’s modest trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- PRAX’s FA Score: 0 green, 5 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 1 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s), and VRTX’s TA Score reflects 3 bullish TA indicator(s).
- JNJ’s TA Score: 1 bullish, 6 bearish.
- PRAX’s TA Score: 4 bullish, 5 bearish.
- VRTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -1.88% price change this week, while PRAX (@Biotechnology) price change was +1.86% , and VRTX (@Biotechnology) price fluctuated -0.56% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
JNJ is expected to report earnings on Apr 14, 2026.
PRAX is expected to report earnings on May 13, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| JNJ | PRAX | VRTX | |
| Capitalization | 574B | 8.81B | 111B |
| EBITDA | 41.1B | -326.06M | 4.87B |
| Gain YTD | 15.838 | 7.261 | -3.770 |
| P/E Ratio | 21.62 | N/A | 28.48 |
| Revenue | 94.2B | 0 | 12B |
| Total Cash | 20.1B | 599M | 6.61B |
| Total Debt | 47.9B | 110K | 2.03B |
JNJ | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 9 | 35 | |
SMR RATING 1..100 | 27 | 39 | |
PRICE GROWTH RATING 1..100 | 42 | 60 | |
P/E GROWTH RATING 1..100 | 78 | 54 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRTX (80) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than VRTX’s over the last 12 months.
JNJ's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is in the same range as VRTX (35) in the Biotechnology industry. This means that JNJ’s stock grew similarly to VRTX’s over the last 12 months.
JNJ's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as VRTX (39) in the Biotechnology industry. This means that JNJ’s stock grew similarly to VRTX’s over the last 12 months.
JNJ's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as VRTX (60) in the Biotechnology industry. This means that JNJ’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (54) in the Biotechnology industry is in the same range as JNJ (78) in the Pharmaceuticals Major industry. This means that VRTX’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | PRAX | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 82% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 90% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 52% | 1 day ago 90% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 40% | 1 day ago 86% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 42% | 1 day ago 88% | 1 day ago 37% |
| Advances ODDS (%) | 3 days ago 44% | 18 days ago 85% | 3 days ago 62% |
| Declines ODDS (%) | 5 days ago 41% | 5 days ago 84% | 5 days ago 42% |
| BollingerBands ODDS (%) | N/A | 1 day ago 90% | 5 days ago 74% |
| Aroon ODDS (%) | 1 day ago 34% | 1 day ago 87% | 1 day ago 28% |
Advertisement
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -1.28% | ||
| BEAM - PRAX | 40% Loosely correlated | +4.18% | ||
| BHVN - PRAX | 37% Loosely correlated | -2.34% | ||
| RAPP - PRAX | 35% Loosely correlated | -0.15% | ||
| VERU - PRAX | 35% Loosely correlated | -2.06% | ||
| RXRX - PRAX | 35% Loosely correlated | -0.91% | ||
More | ||||